Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.

Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
复制标题

DOI:
10.2217/pgs.10.172
复制
发表时间:
2011-03
期刊:
影响因子:
2.1
通讯作者:
Peters GJ
Peters GJ
中科院分区:
医学4区
文献类型:
--
作者:
Lemos C;Giovannetti E;Zucali PA;Assaraf YG;Scheffer GL;van der Straaten T;D'Incecco A;Falcone A;Guchelaar HJ;Danesi R;Santoro A;Giaccone G;Tibaldi C;Peters GJ

文献摘要

参考文献

被引文献

相似文献

目前的研究调查了atp结合盒转运体基因ABCG2的功能多态性是否会影响非小细胞肺癌(NSCLC)患者的吉非替尼活性和/或毒性。为此,对94例接受吉非替尼治疗的NSCLC患者的DNA和肿瘤中ABCG2多态性和表达进行了评估,并分别使用Pearson-χ2和log-rank检验评估其与毒性/反应和进展时间/总生存期的关系。携带ABCG2 - 15622T/T基因型或携带至少一个ABCG2 (1143C/T, - 15622C/T)单倍型TT拷贝的患者发生2/3级腹泻的几率显著增加(p < 0.01)。未发现多态性与预后之间存在关联。与此一致的是,携带不同ABCG2变异的患者之间肿瘤中的ABCG2蛋白水平没有显著差异。ABCG2 - 15622C/T多态性和ABCG2 (1143C/T, - 15622C/T)单倍型导致吉非替尼依赖的中至重度腹泻,这表明应考虑这些药物遗传标记来优化非小细胞肺癌的治疗。
The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. Towards this end, ABCG2 polymorphisms and expression were assessed in DNA and tumors from 94 NSCLC patients treated with gefitinib, whereas their associations with toxicity/response and time-to-progression/overall survival were evaluated using Pearson-χ2 and log-rank-test, respectively. Patients carrying an ABCG2 −15622T/T genotype or harboring at least one TT copy in the ABCG2 (1143C/T, −15622C/T) haplotype developed significantly more grade 2/3 diarrhea (p < 0.01). No associations were found between polymorphisms and outcome. Consistently, ABCG2 protein levels in tumors were not significantly different between patients harboring different ABCG2 variants. The ABCG2 −15622C/T polymorphism and ABCG2 (1143C/T, −15622C/T) haplotype resulted in a gefitinib-dependent, moderate-to-severe diarrhea suggesting that these pharmacogenetic markers should be considered to optimize NSCLC treatment.
DOI: 10.1056/nejmoa040938
发表时间: 2004-05-20
影响因子: 158.5
作者:
Lynch, TJ;Bell, DW;Haber, DA
通讯作者: Haber, DA
DOI: 10.1200/jco.2005.00.6916
发表时间: 2005-08-01
影响因子: 45.3
作者:
Peréz-Soler, R;Saltz, L
通讯作者: Saltz, L
DOI: 10.1023/b:pham.0000045245.21637.d4
发表时间: 2004-10-01
影响因子: 3.7
作者:
Kondo, C;Suzuki, H;Sugiyama, Y
通讯作者: Sugiyama, Y
DOI: 10.1002/path.1203
发表时间: 2002-10-01
影响因子: 7.3
作者:
Diestra, JE;Scheffer, GL;Izquierdo, MA
通讯作者: Izquierdo, MA
DOI: 10.2217/pgs.09.85
发表时间: 2009-10-01
期刊: PHARMACOGENOMICS
影响因子: 2.1
作者:
Keskitalo, Jenni E.;Pasanen, Marja K.;Niemi, Mikko
通讯作者: Niemi, Mikko